This site uses cookies for analytics and to improve your experience. By clicking Accept, you consent to our use of cookies. Learn more in our privacy policy.

You are Here

Three Regulatory Compliance Trends Shaping Supplements in 2025

Regulatory Compliance
Three Regulatory Compliance Trends Shaping Supplements in 2025

Hook: The compliance compass has shifted—quick

If you sell, market, or audit supplements, 2025 felt like a wake-up call: regulators and watchdogs moved from quiet signals to concrete actions that change how products are labeled, promoted, and funded.

Trend 1 — DSHEA disclaimer: less clutter, big relief

What happened? The FDA issued a letter saying it will exercise enforcement discretion on the DSHEA disclaimer placement, meaning the agency won’t insist the statement appear on every panel of a supplement bottle anymore.

Why it matters in practice: For small brands this is a practical win — fewer redesigns, lower packaging costs, and fewer opportunities for plaintiff lawyers to file technical lawsuits.

Real-world example: Trade groups and industry lawyers treated the change like a sigh of relief—companies that had been redesigning every label to repeat the disclaimer can now simplify layouts without fearing immediate enforcement action.

Quick takeaways for teams:

  • Review current labels; prioritize panels that communicate the most to consumers.
  • Keep a single clear DSHEA disclaimer in a prominent place.
  • Document your rationale and alignment with FDA guidance in case of later scrutiny.

Trend 2 — Advertising claims under tighter review (NAD spotlight)

What happened? The National Advertising Division (NAD) issued several decisions in 2025 pushing supplement marketers to back health claims with product‑specific evidence and be careful with sensitive categories such as children’s wellness and sexual health.

Why it matters in practice: Influencer posts, broad “supports brain health” statements, or before/after imagery can trigger challenges—and losing a NAD review often forces rewording or pulled ads, which hits sales and brand trust.

Real-world example: Several DTC brands were publicly challenged for claims around cognitive support and beauty-from-within products, prompting ad copy overhauls and new evidence-gathering strategies.

Quick takeaways for teams:

  • Treat marketing claims as legal assets: have substantiation before you scale a campaign.
  • Audit influencer contracts to control claims and disclosures.
  • Use plain-language consumer benefit statements rather than medical-sounding promises.

Trend 3 — Compliance expectations for grant audits (OMB Compliance Supplement)

What happened? The 2025 OMB Compliance Supplement introduced dual frameworks tied to the October 1, 2024 changes in Uniform Guidance, meaning grant recipients must identify which rules apply to each federal award and prepare for auditor scrutiny accordingly.

Why it matters in practice: Nonprofits and university spinouts receiving federal funding discovered that small timing differences in award dates shift which rules and thresholds apply—this affects internal controls, allowable costs, and Single Audit preparation.

Real-world example: Organizations with multi-year grants had to re-tag expenditures and coordinate earlier with auditors to avoid adjustments during Single Audits.

Quick takeaways for teams:

  • Map grants by award date to the correct Uniform Guidance framework.
  • Update finance and compliance checklists to reflect the new matrices and thresholds.
  • Hold pre-audit walkthroughs with auditors earlier in the cycle.

Practical checklist to act this quarter

  • Label & Packaging: Consolidate DSHEA disclaimer placement; save mockups and legal memos.
  • Marketing & Claims: Compile evidence dossiers for top 5 product claims; review influencer materials.
  • Grants & Audits: Inventory federal awards by award date; run a gap analysis against the 2025 Supplement.

Final note from an expert lens

Compliance is not a one-time fix—think of it as ongoing housekeeping. Regulators are nudging the industry toward clarity and evidence. Brands that treat labeling, advertising, and grant‑management as cross-functional responsibilities will convert these regulatory shifts into competitive advantage.

References:

Share
Facebook Twitter Pinterest Linkedin

You might also like...